Restart Life Sciences transitioned to a revenue-generating business in H1 2026, reporting $465,715 in revenue following its acquisition of Holy Crap Foods. The company saw a 146% revenue increase in Q2 2026 compared to Q1, with Holy Crap's brand growing 64.2% year-over-year. Key developments include listings on Walmart Canada and Amazon US, a Caribbean market pilot, new product launches, and ongoing M&A evaluations. These moves aim to expand market presence and scale operations despite ongoing costs and risks.
Canaccord Genuity maintained a Buy rating on Gold.com but reduced its price target from $70 to $65 due to weaker-than-expected fourth-quarter results. Gold.com reported a strong fiscal 2026 with revenue up 132% to $25.51 billion and net income rising...
Solstice Advanced Materials Inc. ended its $12 billion merger with Element Solutions Inc. after shareholder feedback. Following the cancellation, Jefferies gave Solstice a Buy rating with a $86 price target, indicating a 41% potential gain from the c...
Marshall Tucker, CFO of Smucker, sold 18,482 shares of the company, generating $2.4 million from the sale. This insider transaction may indicate personal financial planning or a shift in confidence, which investors often watch closely. The sale's imp...
Berenberg Bank initiated a 'Buy' rating on Prudential plc with a price target of $39.30, implying a 44% potential gain from its current price of $27.29. Prudential reported strong first-half 2026 results, with adjusted operating profit before tax up ...
Barclays has maintained its Overweight rating on NetApp, reflecting confidence in the company's transition to cloud-focused data infrastructure and strong financial results. The firm raised its price target from $199 to $219, signaling expected stock...
